Kusajili – Centralise les essais cliniques mondiaux

A NOVEL HYBRID PROTOCOL FOR RELAPSED GERM CELL TUMOURS WITH POOR PROGNOSIS 1. To establish the response rates to GAMIO 2. To establish the safety and efficacy of substitution of oxaliplatin and irinotecan for cisplatin and etoposide 3. To establish the toxicity of GAMIO 4. To establish progression free survival (PFS) 5. To ascertain whether a repeat FDG PET-CT scan at 14 days (after 1 cycle of therapy but prior to cycle 2) may predict long-term, progression-free survival following GAMIO.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Postoperative pain relief for primary total knee arthroplasty: A randomised clinical trial of local infiltration anaesthesia followed by intraaticulary infusion compared to epidural infusion To determine wether local infiltrationanaestesia with Naropin added Toradol and Adrenaline combind with intraarticulary infusion of Naropin and Toradol after total knee arthroplasty can enchange analgesia compared with epidural infusion of Naropin and intravenous infusion of Toradol.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III, SUPERIORITY TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ACETYL-L-CARNITINE IN COMBINATION WITH A CISPLATIN CONTAINING CHEMOTHERAPY AS FIRST LINE TREATMENT OF ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER To compare toxicity free survival of patients treated with ALC plus cisplatin-containing CHT versus those treated with placebo plus cisplatin-containing chemotherapy.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with acute leukemia after the first complete response Investigate whether consolidation treatment with repeated courses of azacitidine prolongs leukemia–free survival (LFS) as compared to standard consolidation chemotherapy in elderly (≥65y) patients with AML in CR1.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A Cancer Research UK Phase II Trial to compare [11C]choline and [18F]choline each given as a single administration via intravenous injection for imaging patients with metastatic prostate cancer To compare [18F]choline to [11C]choline in their ability to detect metastatic prostate cancer.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

“TERAPIA ELECTROCONVULSIVA DE CONSOLIDACIÓN ASOCIADA A PSICOFÁRMACOS VERSUS FARMACOTERAPIA EN LA PREVENCIÓN DE RECIDIVAS EN EL TRASTORNO DEPRESIVO MAYOR. UN ENSAYO CLÍNICO, PRAGMÁTICO, PROSPECTIVO ALEATORIZADO” Comparar la eficacia y la seguridad de la TEC-C, en combinación con farmacoterapia, respecto a la observada en pacientes tratados únicamente con psicofármacos en la prevención de recidivas depresivas en pacientes que han requerido terapia electroconvulsiva durante el episodio índice.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Klinische Studie zur Überprüfung des Einflusses einer intradialytischen Verabreichung von Vitamin E und Vitamin C auf biochemische Indikatoren für die antioxidative Kapazität sowie auf Entzündungsmarker und proinflammatorische Zytokine bei Patienten mit Sepsis und akutem Nierenversagen Überprüfung der Auswirkungen einer intradialytischen Verabreichung von Vitamin E und Vitamin C (plus „Membran-Loading“ bereits vor dem Dialysebeginn) auf • biochemische Indikatoren für die antioxidative Kapazität (MDA-LDL IgM, TOC, EPA, Lipidox, Proteinox) und • Entzündungsmarker und proinflammatorische Zytokine (PCT, Neopterin, Interleukine IL6 und IL8)

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Estudio Fase II doble ciego, aleatorizado, de grupos paralelos, de BMS-690514 frente a erlotinib en pacientes con cáncer de pulmón no microcítico previamente tratados con quimioterapia. Revised Protocol Number 01, incorporating amendment 03 + Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 30-Jul-08) + Protocol Amendment 02 FDG-PET Sub-Study (version 1.0 dated 19-Sep-08) To compare the Progression-free survival (PFS) in subjects receiving BMS-690514 relative to erlotinib.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease To evaluate the efficacy of BGC20-1259 (12.5 mg, 25 mg and 50 mg qd) administered for 6 months versus matched placebo

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non Infectious Ocular Inflammation of the Anterior Segment in Patients with Anterior Uveitis To evaluate the safety and efficacy of the 700 µg DEX PS DDS Applicator System (700 µg dexamethasone) and 350 µg DEX PS DDS Applicator System (350 µg dexamethasone) compared with Sham DEX PS DDS Applicator System (needle-less applicator) in the treatment of non-infectious ocular inflammation of the anterior segment in patients with anterior uveitis

• Pays Aucun
• Organes Aucun
• Spécialités Aucun